Brand Name

Carnitor

Generic Name
Levocarnitine
View Brand Information
FDA approval date: December 27, 1985
Classification: Carnitine Analog
Form: Injection, Tablet, Solution

What is Carnitor (Levocarnitine)?

Fatigue, muscle weakness or difficulty recovering from illness can sometimes stem from a problem deep within our body’s energy system, how our cells use fat as fuel. Levocarnitine (also known as L-carnitine) is a naturally occurring nutrient and medication that helps transport fatty acids into cells, where they can be converted into usable energy.

Doctors prescribe Levocarnitine to individuals who cannot produce or maintain enough of it naturally such as those with carnitine deficiency, chronic kidney disease or certain metabolic disorders. It plays a key role in improving energy levels, muscle function and overall well-being. Levocarnitine has been used for decades and is available in both oral and injectable forms.

What does Levocarnitine do?

Levocarnitine helps the body convert fat into energy, a process vital for the heart, muscles and brain. It is primarily used to treat primary and secondary carnitine deficiency, conditions where the body cannot make or maintain adequate carnitine levels.

Doctors may prescribe it for:

  • Genetic carnitine deficiency disorders, where enzyme or transporter defects prevent carnitine production.
  • Patients with chronic kidney disease on dialysis, who lose carnitine through the treatment process.
  • Individuals with certain liver or metabolic conditions, where energy metabolism is impaired.

By restoring normal carnitine levels, Levocarnitine helps reduce fatigue, muscle cramps and weakness, improving physical endurance and overall energy. In some studies, patients with kidney-related deficiencies reported better muscle strength and fewer symptoms of tiredness after consistent therapy (NIH, 2023).

How does Levocarnitine work?

Levocarnitine acts like a transport shuttle that carries long-chain fatty acids into the mitochondria, the cell’s “power plants” where these fats are broken down to generate energy. Without enough carnitine, fats build up in tissues instead of being used efficiently, which can cause weakness, poor metabolism and organ dysfunction.

Clinically, this mechanism is crucial because it helps the heart and skeletal muscles, organs that rely heavily on fat for energy, function optimally. By improving the use of fat as fuel, Levocarnitine can enhance stamina and reduce symptoms of metabolic stress.

Doctors sometimes describe it as “recharging the body’s energy pathways,” particularly in patients whose conditions or medications disrupt normal metabolism.

Levocarnitine side effects

Levocarnitine is generally well tolerated, but some patients may experience mild side effects. Most are temporary and improve as the body adjusts to the medication.

Common side effects include:

  • Nausea or vomiting
  • Diarrhea or stomach cramps
  • Unusual body odor (a “fishy” smell sometimes occurs due to carnitine metabolism)

Less common but possible effects:

  • Headache or dizziness
  • Muscle weakness (especially in patients with uremia)
  • Low blood sugar, particularly in individuals with diabetes

Serious reactions are rare, but patients should seek medical help if they experience chest pain, irregular heartbeat, severe weakness or allergic reactions such as rash or swelling.

Levocarnitine may not be suitable for people with known hypersensitivity to the compound or those with certain metabolic conditions that cause high blood ammonia levels. Always discuss your full medical history with your healthcare provider before starting therapy (FDA, 2024).

Levocarnitine dosage

Levocarnitine comes in several forms: oral tablets, liquid solution and injections. The exact dose and route depend on the cause and severity of the deficiency, age and body weight.

For most patients, therapy begins under medical supervision, and the dosage may be gradually adjusted based on response and lab results. Physicians often monitor:

  • Blood carnitine levels to ensure optimal dosing
  • Kidney and liver function to assess tolerance
  • Muscle strength and fatigue patterns as indicators of clinical improvement

Regular follow-up visits help doctors fine-tune treatment and prevent side effects. Patients on dialysis typically receive injections during or after sessions under medical guidance.

Special care is taken in older adults or those with heart or liver disease to avoid overcorrection or accumulation of the compound.

Does Levocarnitine have a generic version?

Yes. Levocarnitine is available in both generic and brand-name forms. Common brand names include Carnitor® and Carnitor SF®. The generic form, levocarnitine, is FDA-approved and considered equally safe and effective as the branded version.

Generic options are often more affordable and widely available in both oral and injectable preparations, making ongoing treatment easier for patients requiring long-term supplementation.

Conclusion

Levocarnitine is a trusted and effective therapy that supports the body’s energy metabolism, particularly for individuals whose conditions prevent them from producing enough carnitine naturally. By restoring balance to how the body converts fat into fuel, it helps improve strength, stamina, and overall quality of life.

While most people tolerate it well, close medical supervision ensures the right dose and ongoing safety. Patients should always follow their doctor’s instructions and report any unusual symptoms promptly.

When prescribed and monitored by a qualified healthcare professional, Levocarnitine offers a safe and reliable way to help the body maintain its vital energy processes and enhance daily well-being.

References

  1. U.S. Food and Drug Administration (FDA). (2024). Levocarnitine prescribing information. Retrieved from https://www.fda.gov
  2. National Institutes of Health (NIH). (2023). Carnitine: Fact sheet for health professionals. Retrieved from https://ods.od.nih.gov
  3. Mayo Clinic. (2023). Levocarnitine (oral route, intravenous route) description and brand names. Retrieved from https://www.mayoclinic.org
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Clinical Study on Wide Spectrum Micronutrients Supplementation in Patients With Cancer Related Fatigue During Neoadjuvant and Adjuvant Chemotherapy

Summary: The goal of this clinical trial is to test the effect of the administration of APPORTAL® in addition to the SoC (recommended physical exercise), in patients with breast cancer, suffering from fatigue during neoadjuvant and adjuvant chemotherapy. The main questions it aims to answer are: * if the food supplement APPORTAL® can be of help in supporting the physiological energy level, against the fati...

A Randomized, Phase II/III Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS

Summary: Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS). Primary study aim: The clinical objective consists of assessing the efficacy of ALCAR (two different dosages will be tested: 1.5g/day and 3g/day) on the progression of functional disability (loss of self-sufficiency), as measured by...

A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy

Summary: This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolesc...

Brand Information

Carnitor (levocarnitine)
1DESCRIPTION
CARNITOR
The chemical name of levocarnitine is 3-carboxy-2(
chemical-structure
Empirical Formula: C
Molecular Weight: 161.20
Each CARNITOR
Each 118 mL container of CARNITOR
Each 118 mL container of CARNITOR
2CLINICAL PHARMACOLOGY
CARNITOR
Primary systemic carnitine deficiency is characterized by low concentrations of levocarnitine in plasma, RBC, and/or tissues. It has not been possible to determine which symptoms are due to carnitine deficiency and which are due to an underlying organic acidemia, as symptoms of both abnormalities may be expected to improve with CARNITOR
Secondary carnitine deficiency can be a consequence of inborn errors of metabolism. CARNITOR
3PHARMACOKINETICS
In a relative bioavailability study in 15 healthy adult male volunteers, CARNITOR
The plasma concentration profiles of levocarnitine after a slow 3 minute intravenous bolus dose of 20 mg/kg of CARNITOR
The absolute bioavailability of levocarnitine from the two oral formulations of CARNITOR
Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) was a mean of 4.00 L/h.
Levocarnitine was not bound to plasma protein or albumin when tested at any concentration or with any species including the human.
4METABOLISM AND EXCRETION
In a pharmacokinetic study where five normal adult male volunteers received an oral dose of [
After attainment of steady state following 4 days of oral administration of CARNITOR
5INDICATIONS AND USAGE
CARNITOR
CARNITOR
6CONTRAINDICATIONS
None known.
7ADVERSE REACTIONS
The following adverse reactions associated with the use of oral formulations of levocarnitine were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliability, or to establish a causal relationship to drug exposure.
Gastrointestinal Reactions: Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D,L-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhea. Gastrointestinal adverse reactions with CARNITOR® (levocarnitine) Oral Solution or CARNITOR® SF (levocarnitine) Sugar-Free Oral Solution dissolved in liquids might be avoided by a slow consumption of the solution or by a greater dilution. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration, and after any dosage increases.
Musculoskeletal Reactions: Mild myasthenia has been described only in uremic patients receiving D,L-carnitine.
Neurologic Reactions: Seizures have been reported to occur in patients with or without pre-existing seizure activity receiving either oral or intravenous levocarnitine. In patients with pre-existing seizure activity, an increase in seizure frequency and/or severity has been reported.
Hypersensitivity Reactions: Rash, urticaria, and facial edema have been reported with oral CARNITOR® (see WARNINGS).
8OVERDOSAGE
There have been no reports of toxicity from levocarnitine overdosage. Levocarnitine is easily removed from plasma by dialysis. The intravenous LD
9DOSAGE AND ADMINISTRATION
CARNITOR
Adults: The recommended oral dosage for adults is 990 mg two or three times a day using the 330 mg tablets, depending on clinical response.
Infants and children: The recommended oral dosage for infants and children is between 50 and 100 mg/kg/day in divided doses, with a maximum of 3 g/day. Dosage should begin at 50 mg/kg/day. The exact dosage will depend on clinical response.
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.
CARNITOR
For oral use only. Not for parenteral use.
Adults: The recommended dosage of levocarnitine is 1 to 3 g/day for a 50 kg subject, which is equivalent to 10 to 30 mL/day of CARNITOR
Infants and children: The recommended dosage of levocarnitine is 50 to 100 mg/kg/day which is equivalent to 0.5 mL/kg/day CARNITOR
CARNITOR
10HOW SUPPLIED
CARNITOR
CARNITOR
CARNITOR
Rx only.
11REFERENCES
  1. Bohmer, T., Rydning, A. and Solberg, H.E. 1974. Carnitine levels in human serum in health and disease.
  2. Brooks, H., Goldberg, L., Holland, R.
  3. Christiansen, R., Bremer, J. 1976. Active transport of butyrobetaine and carnitine into isolated liver cells.
  4. Lindstedt, S. and Lindstedt, G. 1961. Distribution and excretion of carnitine in the rat.
  5. Rebouche, C.J. and Engel, A.G. 1983. Carnitine metabolism and deficiency syndromes.
  6. Rebouche, C.J. and Paulson, D.J. 1986. Carnitine metabolism and function in humans.
  7. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. 1989.
  8. Schaub, J., Van Hoof, F. and Vis, H.L. 1991.
  9. Marzo, A., Arrigoni Martelli, E., Mancinelli, A., Cardace, G., Corbelletta, C., Bassani, E. and Solbiati, M. 1991. Protein binding of L-carnitine family components.
  10. Rebouche, C.J. 1991. Quantitative estimation of absorption and degradation of a carnitine supplement by human adults.
Leadiant Logo
PREVIOUS EDITION IS OBSOLETE
Date of Issue: 07/23 OPI-16
12PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label
NDC 54482-145-08
CARNITOR
(levocarnitine) Oral Solution
118 mL (4 fl. oz.)
Active ingredient: L-carnitine 1 g/10 mL
Inactive ingredients: Artificial Cherry
Leadiant
Avoid excess heat. Protect from freezing. Store at
Distributed by:
OS(Ha)-2 06/20
1572-01
PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label
13PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label - NDC 54482-145-09
118 mL (4 fl. oz.)
CARNITOR
1 g/10 mL
Rx only.
Active ingredient: L-carnitine 1 g/10 mL
Inactive ingredients: Artificial Cherry
Avoid excess heat. Protect from freezing.
Dosage: See Prescribing Information.
Distributed by: Leadiant Biosciences, Inc.
OS(Ha)-5
1572-03
PRINCIPAL DISPLAY PANEL - 118 mL Bottle Label - NDC 54482-145-09